Huro Biotech Joint Stock Company
2 clinical trials · Sponsor
◉ Watch Huro Biotech Joint Stock Company
| Record | Firm | Date |
|---|---|---|
| Safety and Efficacy of DSM 32444 Postbiotic in the Treatment of Acute Rhinosinusitis (NCT05999955) | Huro Biotech Joint Stock Company | 2022-12-29 |
| Safety Evaluation of Intranasal Use of DSM 32444 Postbiotic in Humans (NCT05984004) | Huro Biotech Joint Stock Company | 2022-09-26 |
Track Huro Biotech Joint Stock Company automatically
Every clearance here is in the API, with alerts when new ones post.